'I Still Can't Believe It's Around': Cramer Rips Plug Power

On CNBC's “Mad Money Lightning Round,” on Tuesday, Jim Cramer said Sempra (NYSE:SRE) is a buy.Supporting his view, Wells Fargo analyst Shahriar Pourreza initiated coverage of Sempra on Tuesday with an Overweight rating and a price target of $115.“You can own it, they've got to figure out something,” Cramer said when asked about Pfizer Inc. (NYSE:PFE). “That yield will protect you for a while though.”Pfizer announced on Oct. 14 the initial results from a clinical trial called HER2CLIMB-05.  This trial tested ...